Terns Pharmaceuticals, Inc.
News
Terns Pharmaceuticals (NASDAQ:TERN) Hits New 52-Week High Following Analyst Upgrade
Zolmax Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report)'s share price reached a new 52-week high during trading on Tuesday after JMP Securities raised their price target on the stock from $15.00...\n more…
JMP Securities Increases Terns Pharmaceuticals (NASDAQ:TERN) Price Target to $20.00
Ticker Report Terns Pharmaceuticals (NASDAQ:TERN - Get Free Report) had its price objective increased by research analysts at JMP Securities from $15.00 to $20.00 in a research report issued on Tuesday, Benzinga...\n more…
Terns Pharmaceuticals prices $150M stock offering
SeekingAlpha.com: All News Terns Pharmaceuticals prices upsized public offering at $10.50 per share, expecting gross proceeds of $150.15M.\n more…
Terns Pharmaceuticals (NASDAQ:TERN) Hits New 12-Month High on Analyst Upgrade
Ticker Report Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) shares hit a new 52-week high on Tuesday after JMP Securities raised their price target on the stock from $15.00 to $20.00. JMP Securities...\n more…
Terns Announces Pricing of Upsized $150.15 Million Public Offering
Globe Newswire FOSTER CITY, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ( Terns or the Company ) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...\n more…
Terns Stock Soars on Positive Data From Phase I Study of Obesity Drug
Benzinga Shares of Terns Pharmaceuticals (NASDAQ: TERN), a clinical-stage company, soared 16.8% after the company announced positive top-line data from the early-stage single and multiple-ascending dose (SAD and MAD) obesity study.\n more…